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1. STROKE {#jnr24333-sec-0001}
=========

Stroke is a global health concern that leads to permanent disability in approximately 30% of survivors (Weinstein, Koerner, & Möller, [2010](#jnr24333-bib-0079){ref-type="ref"}). It has devastating complications arising from either a sudden loss of blood supply to the brain (ischemic stroke) or rupturing of blood vessels in the brain (hemorrhagic stroke) (Deb, Sharma, & Hassan, [2010](#jnr24333-bib-0016){ref-type="ref"}). Stroke leads to the induction of inflammatory cascade via migration of activated microglia to the ischemic core, worsening its outcomes (Perera et al., [2006](#jnr24333-bib-0063){ref-type="ref"}). The narrow therapeutic window and insufficiency to recover or protect the dying neurons are certain limitations of current treatment strategies for stroke, so there is an urgent need for an alternative approach (Fann et al., [2013](#jnr24333-bib-0021){ref-type="ref"}; Kaur et al., [2018](#jnr24333-bib-0042){ref-type="ref"}). The limitation to improve the aggravated inflammatory condition by currently used thrombolytic agents necessitates newer treatment options for stroke (Carroll, [2009](#jnr24333-bib-0011){ref-type="ref"}). Interferon‐β is known to have immunomodulatory and anti‐inflammatory properties and can be explored for improving conditions after stroke (Dhib‐Jalbut & Marks, [2010](#jnr24333-bib-0018){ref-type="ref"}). IFN‐β plays a role as an anti‐inflammatory agent through several immune cascades. IFN‐β significantly helps in obviating neuro‐inflammatory conditions of the central nervous system and improves the pathogenesis of many neurological conditions. A report suggested its role in decreasing neuronal cell death and increasing functional recovery attenuating inflammation after stroke onset (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}).

2. INTERFERON {#jnr24333-sec-0002}
=============

Interferons (IFNs) are signaling proteins belonging to a family of cytokines (Nallar & Kalvakolanu, [2014](#jnr24333-bib-0062){ref-type="ref"}). IFNs are actively engaged in altering the cellular immune system against the viral infections of host cells (Fritsch & Weichhart, [2016](#jnr24333-bib-0025){ref-type="ref"}). IFNs generally act against extracellular biomolecules via the stimulation of Toll‐like receptors (TLRs) and amplify the antigen presentation to specific T cells. They act by both paracrine and autocrine modes for the regulation of acquired and innate immunity via stimulation of intercellular and intracellular networks providing resistance to certain viral infections and maintenance of normal cell survival and tumor cell death (Le, Genin, Baines, & Hiscott, [2000](#jnr24333-bib-0053){ref-type="ref"}).

2.1. Types of interferons and their signaling pathways {#jnr24333-sec-0003}
------------------------------------------------------

Interferons have been classified according to their structural homology and receptor types as type I, II, and III. Type I IFNs include alpha (α), beta (β), delta (δ), epsilon (Ɛ), kappa (κ), and omega (ω). Type‐II IFNs include gamma (γ) and type‐III, also known as IFN‐lambda (λ), have interferon‐like activities (Kopitar‐Jerala, [2017](#jnr24333-bib-0046){ref-type="ref"}; Wack, Terczyńska‐Dyla, & Hartmann, [2015](#jnr24333-bib-0076){ref-type="ref"}). Type‐I IFNs α and β act by binding to interferon alpha‐receptors (IFNARs). The IFNAR is a heterodimeric transmembrane receptor consisting of two subunits that is, IFNAR1 and IFNAR2 (Sheppard et al., [2003](#jnr24333-bib-0069){ref-type="ref"}). The binding of IFNs α and β with the IFNAR leads to the activation of receptor‐associated protein tyrosine kinases. Janus kinase 1 and tyrosine kinase 2 in turn phosphorylate the signal transducer and activator of transcription 1 (STAT1) and 2 (STAT2). Activation of STAT 1 and 2 is followed by dimerization and translocation into the nucleus and, by combining with IFN‐regulatory factor 9, forms a trimolecular complex called IFN‐stimulated gene factor 3 (ISGF3). This ISGF3 further binds to DNA sequences, which are known as IFN‐stimulated response elements, and directly activates the transcription of ISGs. The signal decays within a period of hours and the STATs are exported back to the cytoplasm for the next signaling process (Figure [1](#jnr24333-fig-0001){ref-type="fig"}). Other key regulators of the IFN signaling cascade are the negative regulators which cover different mechanisms that suppress type I IFN‐mediated expressions such as suppressor of cytokines signaling (SOCS) and ubiquitin carboxy‐terminal hydrolase 18 (USP 18) (Kopitar‐Jerala, [2017](#jnr24333-bib-0046){ref-type="ref"}; Schreiber & Piehler, [2015](#jnr24333-bib-0068){ref-type="ref"}) (Table [1](#jnr24333-tbl-0001){ref-type="table"}).

![Interferon signaling pathway. Binding of IFNs (α and β) with IFNAR (Interferon‐α/β receptor): Activation of receptor‐associated protein tyrosine kinase. (a) Janus kinase‐1. (b) Tyrosine kinase‐2. (c) Signaling pathway through TRIF. These two protein tyrosine kinases start phosphorylation of signal transducer and activator of transcription1 STAT1 & STAT2. Activation of STAT1 & STAT2. Dimerization and translocation of STAT1 & STAT2 to the nucleus. Formation of trimolecular complex together with IFN‐regulatory factor‐9 (IRF‐9) that is, IFN‐stimulated gene factor‐3 (ISGF3). Binding of ISGF‐3 with DNA sequence called as IFN‐stimulated response elements. These IFN‐stimulated response elements activate transcription of ISGs directly and regulate signaling of IFNs. Within hours signal decays and STATs return to cytoplasm for next signaling pathway. TLR 4 mediated IFN‐β activation through TRIF‐dependent pathway via Interferon regulatory factor 3 (IRF‐3) \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](JNR-97-116-g001){#jnr24333-fig-0001}

###### 

Types of human IFN and IFN‐like proteins

  Ligand types        Names    Receptor chain 1   Receptor chain 2
  ------------------- -------- ------------------ ------------------
  IFN (Type‐I)        IFN‐α    IFN‐α R1/IFNAR1    IFN‐α R2/IFNAR2
                      IFN‐β                       
                      IFN‐k                       
                      IFN‐ε                       
                      IFN‐ω                       
                      IFN‐v                       
  IFN (Type‐II)       IFN‐γ    IFN‐γ R1           IFN‐γ R2
  IFN‐like proteins   IL‐28A   IL‐28R1            IL‐10R2
                      IL‐28B                      
                      IL‐29                       
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### 2.1.1. Role of interferons {#jnr24333-sec-0004}

Type I IFNs (IFN‐α and IFN‐β) exhibit a wide breadth of biological activities (antiviral, anti‐inflammatory, and anti‐proliferative) (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}). The latter occurs via cytotoxic stimulation of numerous cells of the immune system such as natural killer cells, monocytes, T cells, macrophages, and dendritic cells. IFNs can also upregulate the cell surface expression of major histocompatibility complex (MHC) antigens and tumor‐associated surface antigens. It helps in the induction or activation of pro‐apoptotic genes and proteins (Bak, Bax, TNF‐related apoptosis‐inducing ligand (TRAIL), and caspases) as well as the repression or reduction of anti‐apoptotic genes such as inhibitor of apoptosis protein (IAP) and B‐cell lymphoma 2 (Bcl‐2), responsible for cell proliferation and differentiation and anti‐angiogenic activity (Pestka, [2007](#jnr24333-bib-0064){ref-type="ref"}).

IFNs have been recognized to be deeply implicated in the pathogenesis of several diseases, for example, collagen diseases such as rheumatoid arthritis (Conigliaro et al., [2010](#jnr24333-bib-0013){ref-type="ref"}), systemic lupus erythematosus (SLE) (Gao, Anolik, & Looney, [2018](#jnr24333-bib-0026){ref-type="ref"}), multiple sclerosis (Rudick & Goelz, [2011](#jnr24333-bib-0066){ref-type="ref"}), insulin‐dependent diabetes mellitus (Qaisar, Jurczyk, & Wang, [2018](#jnr24333-bib-0065){ref-type="ref"}), pancreatic cancer (Booy, Hofland, & van Eijck, [2015](#jnr24333-bib-0009){ref-type="ref"}), fulminant hepatitis (Borst et al., [2018](#jnr24333-bib-0010){ref-type="ref"}), atherosclerosis (Moss & Ramji, [2017](#jnr24333-bib-0061){ref-type="ref"}), and allergic diseases (Gonzales‐van Horn & Farrar, [2015](#jnr24333-bib-0031){ref-type="ref"}). IFNs are clinically used in the therapy against viral infections such as hepatitis B and C (Asselah & Marcellin, [2018](#jnr24333-bib-0004){ref-type="ref"}; Jaeckel et al., [2001](#jnr24333-bib-0038){ref-type="ref"}) and for different malignancies (Baron et al., [1991](#jnr24333-bib-0007){ref-type="ref"}; Imanishi, [1994](#jnr24333-bib-0036){ref-type="ref"}).

#### Interferon‐β {#jnr24333-sec-0005}

Interferon‐β (IFN‐β), a broadly expressed cytokine, was approved by the US FDA in the past for the relapsing‐remitting multiple sclerosis (RRMS) treatment for more than a decade (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}). IFN‐β drives innate immunity, acting in response to pathogenic attack or injury via activation of both pro‐and anti‐inflammatory cytokines. Currently, research is being conducted to find a protective role of IFN‐β in several diseases such as ischemic stroke, subarachnoid hemorrhage, colitis, colorectal cancer (Kotredes, Thomas, & Gamero, [2017](#jnr24333-bib-0047){ref-type="ref"}; Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}; Tiebosch et al., [2013](#jnr24333-bib-0074){ref-type="ref"}) along with other conditions (Table [2](#jnr24333-tbl-0002){ref-type="table"}) (68), such as anti‐inflammatory (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}), antiviral (Kraus & Oschmann, [2006](#jnr24333-bib-0048){ref-type="ref"}; Samuel, [2001](#jnr24333-bib-0067){ref-type="ref"}), immuno modulatory (Kasper & Reder, [2014](#jnr24333-bib-0041){ref-type="ref"}), anti‐proliferative (Dierckx et al., [2017](#jnr24333-bib-0019){ref-type="ref"}), anti‐angiogenic (Friedman, [2008](#jnr24333-bib-0024){ref-type="ref"}), and cell differentiation (Kraus & Oschmann, [2006](#jnr24333-bib-0048){ref-type="ref"}) (see Table [2](#jnr24333-tbl-0002){ref-type="table"}).

###### 

Clinical trials of interferon beta‐1b and interferon beta‐1a

  Sr. No             Phase         Status                  Condition                                                                          Count   References
  ------------------ ------------- ----------------------- ---------------------------------------------------------------------------------- ------- ----------------------------
  Interferon‐β                                                                                                                                        
  *Interferon‐β1b*                                                                                                                                    
  1\.                I             Completed               Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  2\.                I             Completed               Human Immuno‐deficiency Virus Infections (HIV)/Kaposis Sarcoma                     I       <https://www.drugbank.ca/>
  3\.                I, II         Completed               Acute Respiratory Distress Syndrome (ARDS)/Acute Lung Injury (ALI)                 I       <https://www.drugbank.ca/>
  4\.                II            Completed               Disseminated Sclerosis                                                             III     <https://www.drugbank.ca/>
  5\.                II            Completed               Disseminated Sclerosis/Relapsing‐Remitting Multiple Sclerosis (RRMS)               I       <https://www.drugbank.ca/>
  6\.                II            Completed               Heart Disease/Prophylaxis of Cardiomyopathy                                        I       <https://www.drugbank.ca/>
  7\.                II            Completed               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      I       <https://www.drugbank.ca/>
  8\.                II            Completed               Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  9\.                II, III       Not known               Disseminated Sclerosis/Relapsing‐Remitting Multiple Sclerosis (RRMS)               I       <https://www.drugbank.ca/>
  10\.               II, III       Recruiting              Middle East Respiratory Syndrome Coronavirus (MERS‐Coronavirus)                    I       <https://www.drugbank.ca/>
  11\.               II, III       Recruiting              Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  12\.               III           Terminated              Disseminated Sclerosis                                                             II      <https://www.drugbank.ca/>
  13\.               III           Completed               Human Immunodeficiency Virus Infections                                            I       <https://www.drugbank.ca/>
  14\.               III           Completed               Relapsing‐Remitting Multiple Sclerosis (RRMS                                       II      <https://www.drugbank.ca/>
  15\.               III           Completed               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      I       <https://www.drugbank.ca/>
  16\.               III           Terminated              Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  17\.               IV            Withdrawn               Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  18\.               IV            Completed               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      IV      <https://www.drugbank.ca/>
  19\.               IV            Completed               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      I       <https://www.drugbank.ca/>
  20\.               IV            Terminated              Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      I       <https://www.drugbank.ca/>
  *Interferon‐β1a*                                                                                                                                    
  1\.                0             Completed               Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  2\.                I             Completed               Healthy volunteers                                                                 II      <https://www.drugbank.ca/>
  3\.                I             Completed               Cerebrovascular Accidents                                                          I       <https://www.drugbank.ca/>
  4\.                I             Completed               Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  5\.                I             Completed               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      II      <https://www.drugbank.ca/>
  6\.                II            Completed               Disseminated Sclerosis                                                             V       <https://www.drugbank.ca/>
  7\.                II            Completed               Asthma Bronchial                                                                   I       <https://www.drugbank.ca/>
  8\.                II            Completed               Alzheimer\'s Disease (AD)                                                          I       <https://www.drugbank.ca/>
  9\.                II            Completed               Polyradiculoneuropathy, Chronic Inflammatory Demyelinating                         I       <https://www.drugbank.ca/>
  10\.               II            Completed               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      III     <https://www.drugbank.ca/>
  11\.               II            Completed               Ulcerative Colitis (UC)                                                            II      <https://www.drugbank.ca/>
  12\.               II            Terminated              Crohn's Disease (CD)                                                               I       <https://www.drugbank.ca/>
  13\.               II            Withdrawn               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      I       <https://www.drugbank.ca/>
  14\.               II, III       Active Not Recruiting   Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  15\.               II, III       Recruiting              Disseminated Sclerosis/Relapsing‐Remitting Multiple Sclerosis (RRMS)               I       <https://www.drugbank.ca/>
  16\.               III           Completed               Disseminated Sclerosis                                                             III     <https://www.drugbank.ca/>
  17\.               III           Completed               Chronic Hepatitis‐C Infection                                                      I       <https://www.drugbank.ca/>
  18\.               III           Completed               Clinically Isolated Syndrome (CIS)                                                 I       <https://www.drugbank.ca/>
  19\.               III           Recruiting              Respiratory Distress Syndrome, Adult                                               I       <https://www.drugbank.ca/>
  20\.               III           Terminated              Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      I       <https://www.drugbank.ca/>
  21\.               III           Terminated              Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  22\.               III           Withdrawn               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      I       <https://www.drugbank.ca/>
  23\.               IV            Completed               Disseminated Sclerosis                                                             V       <https://www.drugbank.ca/>
  24\.               IV            Completed               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      XII     <https://www.drugbank.ca/>
  25\.               IV            Completed               Clinically Isolated Syndrome (CIS)/Relapsing‐Remitting Multiple Sclerosis (RRMS)   I       <https://www.drugbank.ca/>
  26\.               IV            Terminated              Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      I       <https://www.drugbank.ca/>
  27\.               IV            Terminated              Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
  28\.               IV            Withdrawn               Demyelinating Disorders/Disseminated Sclerosis/Neuritis/Optic Neuritis             I       <https://www.drugbank.ca/>
  29\.               IV            Withdrawn               Relapsing‐Remitting Multiple Sclerosis (RRMS)                                      II      <https://www.drugbank.ca/>
  30\.               Unavailable   Withdrawn               Disseminated Sclerosis                                                             I       <https://www.drugbank.ca/>
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2.2. Interferon‐beta (IFN‐β): Mechanistic roles and actions {#jnr24333-sec-0006}
-----------------------------------------------------------

Neurodegeneration is mostly triggered by numerous inflammatory mediators that can lead to neurological pathologies including ischemic stroke (Zipp & Aktas, [2006](#jnr24333-bib-0084){ref-type="ref"}). Inflammation is initiated by the release of various inflammatory mediators; activation of intravascular leukocytes helps in the infiltration of immune cells in the CNS (Anrather & Iadecola, [2016](#jnr24333-bib-0002){ref-type="ref"}; Kieseier, [2011](#jnr24333-bib-0044){ref-type="ref"}). Immune cells migration across the blood--brain barrier (BBB) causes breakdown of the BBB due to the release of numerous cytotoxic agents like cytokines, matrix metalloproteinase, nitric oxide (NO), and reactive oxygen species (ROS), leading to demyelination and axonal injury which are common outcomes of neurodegeneration (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}). Although the damage caused to neurons is not reparable, immunomodulatory therapies have been reported to decrease inflammation (Markowitz, [2007](#jnr24333-bib-0056){ref-type="ref"}). IFN‐β, a polypeptide produced by fibroblasts, attaches to its specific receptor and initiates a complex transcriptional reaction producing a pharmacological response at the site of injury. Markowitz reported that IFN‐β helps in suppressing antigen presentation, decreasing T cell proliferation, and altering cytokine and matrix metalloproteinase expression (Kieseier, [2011](#jnr24333-bib-0044){ref-type="ref"}; Markowitz, [2007](#jnr24333-bib-0056){ref-type="ref"}).

IFN‐β helps in the elevation of concentration and expression of anti‐inflammatory agents while it down‐regulates the pro‐inflammatory cytokine expression (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}). A systemic application of IFN‐β may reduce the increased cell count of inflammatory cells across the BBB and help raise nerve growth factor (NGF) levels, ultimately resulting in a dramatic increase in the survival of neurons (Kieseier, [2011](#jnr24333-bib-0044){ref-type="ref"}). IFN‐β may also help in raising the CD56^bright^ natural killer cell count: these cells produce anti‐inflammatory mediators very efficiently and have the capacity to mitigate neuronal inflammation in the peripheral blood circulation. With various mechanistic approaches, IFN‐β manifests to be clinically relevant by reducing lesions, decreasing the risk of sustained disability progression, and decreasing brain atrophy (Kieseier, [2011](#jnr24333-bib-0044){ref-type="ref"}).

Cerebral ischemia is responsible for producing various immune cell mediators which can exacerbate ischemic brain injury. These various inflammatory mediators, under certain situations, may induce tolerance to cerebral ischemia. Mediators like proinflammatory cytokines for example, interleukin 1 (IL‐1), tumor necrosis factor (TNF), and damage‐associated molecular patterns (DAMPs) are responsible for the activation of intracellular signaling pathways which mediate stress responses (Anrather & Iadecola, [2016](#jnr24333-bib-0002){ref-type="ref"}). Immune cell therapies are highly explored in not only preclinical but also clinical settings for various acute injuries related with the CNS, including stroke (Bang, [2016](#jnr24333-bib-0006){ref-type="ref"}; George & Steinberg, [2015](#jnr24333-bib-0029){ref-type="ref"}). IFN‐β is immunomodulatory and helps regulate the function of immune cells in ischemic stroke.

IFN‐β modulates antigen presenting cells (APCs) to reduce antigen presentation and stimulation of T cells (Jiang et al., [1995](#jnr24333-bib-0039){ref-type="ref"}). IFN‐β directly affects T cells and inhibits adhesion of molecules like intercellular adhesion molecule (ICAM) and vascular adhesion molecule (VCAM) to the BBB and passage through the same (Dhib‐Jalbut & Marks, [2010](#jnr24333-bib-0018){ref-type="ref"}). B cells secrete inflammatory mediators that are responsible for stimulating plasma cells to produce immunoglobulins (IGs) in the cerebrospinal fluid (CSF) (Dalakas, [2008](#jnr24333-bib-0015){ref-type="ref"}). B cell activating factor (BAFF), belonging to the TNF family, is upregulated in the blood (Krumbholz et al., [2008](#jnr24333-bib-0049){ref-type="ref"}) and is crucial for maintaining B cells level at the inflammation site and can aggravate local inflammation by facilitating B cell survival (Krumbholz et al., [2005](#jnr24333-bib-0050){ref-type="ref"}). IFN‐β modulates B‐cell function which can alter antigen presentation. Expression of MHC II on B cells is reduced post‐therapy with the help of IFN‐β through a decrease in CD80 expression that inhibits antigen presentation to CD8+T cells (Genç, Dona, & Reder, [1997](#jnr24333-bib-0028){ref-type="ref"}; Jiang et al., [1995](#jnr24333-bib-0039){ref-type="ref"}). IFN‐β treatment results in the upregulation of CD86 expressing B cells and contributes to the reduction of type 1 T helper (Th1) cell secretion of inflammatory cytokines (Huang, Ito, Dangond, & Dhib‐Jalbut, [2013](#jnr24333-bib-0035){ref-type="ref"}). Levels of BAFF are also upregulated in blood leukocytes and serum with IFN‐β therapy, showing elevated B cell function (Krumbholz et al., [2008](#jnr24333-bib-0049){ref-type="ref"}). With the correct combination of stimuli, it can lead to increased B cell secretion of anti‐inflammatory cytokines like IL‐8 and IL‐10, suggesting that IFN‐β can increase CD4 and CD8 regulatory T cells along with regulatory B cells (Meinl, Krumbholz, & Hohlfeld, [2006](#jnr24333-bib-0059){ref-type="ref"}).

3. ISCHEMIC STROKE AND INTERFERON‐β: CROSSTALK {#jnr24333-sec-0007}
==============================================

3.1. Ischemic cascade {#jnr24333-sec-0008}
---------------------

Cell death following brain ischemia is mediated by a diverse group of etiologies such as severe focal hypoperfusion that eventually results into excitotoxicity and oxidative damage (Lakhan, Kirchgessner, & Hofer, [2009](#jnr24333-bib-0052){ref-type="ref"}). These events are responsible for causing microvascular injury, BBB dysfunction, and elicit inflammation after ischemia. Events of such kind worsen the primary injury and may result in severe cerebral damage. The extent of permanent cerebral damage relies upon different factors such as ischemic duration, infarct volume, along with the auto‐repairing capability of the brain (Dirnagl, Iadecola, & Moskowitz, [1999](#jnr24333-bib-0020){ref-type="ref"}; Lakhan et al., [2009](#jnr24333-bib-0052){ref-type="ref"}).

The responses after inflammatory cascade that worsen the cerebral injury post‐ischemia is an interesting target for therapeutics, as inflammation increases over time and is strongly involved in the exacerbation of neuronal outcomes (Jin, Yang, & Li, [2010](#jnr24333-bib-0040){ref-type="ref"}). It has been reported that post‐ischemia, systemically applied IFN‐β helps in attenuating brain infarct progression (Veldhuis et al., [2003](#jnr24333-bib-0075){ref-type="ref"}).

During the sub‐acute phase of ischemia, resident microglial cells (MGs) and peripheral inflammatory cells infiltrate into the surrounding and core region of the infarct area of the brain, leading to secondary neurodegeneration (Weinstein et al., [2010](#jnr24333-bib-0079){ref-type="ref"}). The onset of ischemia is mainly linked with the extravasation of plasma‐derived protein, bioactive phospholipids, BBB disruption, and prompt resident MG activation and infiltration into the ischemic site. These multifarious events lead to the activation of pro‐inflammatory cytokines like chemokines (C‐C motif) ligand 2 (CCL2), chemokine (C‐C motif) ligand 3 (CCL3), TNF‐α, IL‐1b, and endogenous NO release at the injury site, culminating in neuronal death (Denes, Thornton, Rothwell, & Allan, [2010](#jnr24333-bib-0017){ref-type="ref"}; Weinstein et al., [2010](#jnr24333-bib-0079){ref-type="ref"}).

3.2. Neuroprotective role of IFN‐β in Ischemic stroke {#jnr24333-sec-0009}
-----------------------------------------------------

CNS inflammation induced due to ischemic conditions plays an essential role in stroke pathophysiology and exacerbates infarct formation at the injury site (Amantea et al., [2015](#jnr24333-bib-0001){ref-type="ref"}; Benakis, Garcia‐Bonilla, Iadecola, & Anrather, [2015](#jnr24333-bib-0008){ref-type="ref"}; Kawabori & Yenari, [2015](#jnr24333-bib-0043){ref-type="ref"}). IFN‐β markedly reduces infarct size by inhibition of the production of inflammatory cytokines such as IL‐6, IL‐23p19, IL‐1b, and TNF‐α; all of these cytokines are found to be increased in the ipsilateral part of the ischemic brain (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}) (Figure [2](#jnr24333-fig-0002){ref-type="fig"}). Endogenous IFN‐β signaling limits local inflammation, regulates peripheral immune cells, and, thereby, may contribute positively to stroke outcome (Inácio et al., [2015](#jnr24333-bib-0037){ref-type="ref"}).

![Mechanism of action of IFN‐β. (a) After ischemic injury, immune cells like mast cells, macrophages, and neutrophils from the circulation release the inflammatory cytokines. These inflammatory cytokines include IL‐6, IL‐4, IL‐1B, IL‐23p9, and TNF‐α. At ischemic injury site, there is over‐expression of these inflammatory cytokines. These overexpressed inflammatory cytokines lead to CNS inflammation. Increased CNS inflammation results in infarct formation in the brain. IFN‐β helps in suppressing overexpressed inflammatory cytokines and ultimately helps in reducing the brain infarct in ischemic brain. (b) After an ischemic injury on the ipsilateral side of the hemisphere, there are increased expressions of IBA1 (specifically expressed in microglial cells (MGs), helps in MG regulation) in the cortex. Increased IBA1 results in the transformation of resting MGs to reactive MGs. Reactive MGs influence release of inflammatory cytokines, for example, IL‐6, IL‐4, IL‐1B, IL‐23p9, and TNF‐α leads to cytotoxicity which in turn results in infarct formation in the brain at the injury site. IFN‐β inhibits upregulated IBA1 expression in the cortex of ipsilateral side and reduces the MG activation in the ischemic brain \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](JNR-97-116-g002){#jnr24333-fig-0002}

Rapidly activated MGs in response to ischemic injury are a major factor for the production of inflammatory mediators and increased phagocytosis. Activated MGs trigger innate immune responses followed by increased production of matrix metalloproteinase (MMPs), leading to BBB damage. These inflammatory mediators cause various cytotoxic effects due to the increased expression of inflammatory cytokines at the ischemic site (Benakis et al., [2015](#jnr24333-bib-0008){ref-type="ref"}; Xia, Han, Huang, & Ying, [2010](#jnr24333-bib-0081){ref-type="ref"}). Recent findings report that during cerebral ischemia, activated MGs exhibit a high level of ionized calcium‐binding adapter molecule 1 (IBA1) expression, confirmed by confocal images showing round and amoeboid shaped morphology with very short processes and bigger soma in the cortex of the ipsilateral hemisphere (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}). IFN‐β treatment helps in the suppression of lBA1 expression by reducing MG activation at the site of injury, there by showing ramified morphology with longitudinally branched and smaller soma. Kuo et al. found that IFN‐β's inhibitory effect on activation of MG is due to a reduction in the expression of pro‐inflammatory cytokines interleukin 23p19 (IL‐23p19), IL‐1b, IL‐6, and TNF‐α at the site of infarct (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}) (Figure [2](#jnr24333-fig-0002){ref-type="fig"}).

A study carried out by Cruz et al. reported that IFN‐β requires IFN regulatory factor 2 binding protein 2 (IRF2BP2) to limit ischemic stroke injury. Mice lacking IRF2BP2‐deficient microglia/macrophages lost the anti‐inflammatory property of IFN‐β, which failed to protect them from ischemic injuries (Cruz et al., [2017](#jnr24333-bib-0014){ref-type="ref"}). Recent work has identified that TLRs and type 1 IFN signaling mediate neuroprotection in both ischemia/reperfusion and ischemic preconditioning (IPC) (McDonough et al., [2017](#jnr24333-bib-0057){ref-type="ref"}). It has been reported that in a mouse model of ischemic injury type 1, IFN signaling is essential for IPC‐directed neuroprotection in white matter (Hamner et al., [2015](#jnr24333-bib-0032){ref-type="ref"}) and gray matter (Stevens et al., [2011](#jnr24333-bib-0072){ref-type="ref"}). McDonough et al. proposed that during ischemia/reperfusion injury MGs lead to the activation of endogenous neuroprotection pathways which are dependent on the IFN‐stimulated genes (ISGs) response (McDonough & Weinstein, [2016](#jnr24333-bib-0058){ref-type="ref"}). Wang et al. ([2017](#jnr24333-bib-0077){ref-type="ref"}) reported that by promoting expression of TIR‐domain containing adapter‐inducing interferon‐β (TRIF) with the compound Dexmedetomidine improved stroke recovery, supporting the beneficial effect of interferon‐beta in ischemic stroke (Wang et al., [2017](#jnr24333-bib-0077){ref-type="ref"}).

Experimental preconditioning models are robust and primarily focus on neuroprotective actions (Gesuete et al., [2012](#jnr24333-bib-0030){ref-type="ref"}). Gesuete et al., uncovered the protective preconditioning effect of polyinosinic polycytidylic acid (poly‐ICLC) against cerebral ischemic injury. They found that treatment with poly‐ICLC in in vitro and in vivo ischemia models induced IFN‐β mRNA expression and type I IFN signaling in brain microvascular endothelial cells, which attenuated BBB dysfunction and was required for neuroprotection against ischemic injury (Gesuete et al., [2012](#jnr24333-bib-0030){ref-type="ref"}).

During ischemic injury, chemokine induction enhances the peripheral immune cell recruitment to the ischemic brain. Chemokines, including monocyte chemoattractant protein‐1 (MCP‐1), macrophage inflammatory protein‐1α (MIP‐1α), CCL2, and CCL3 are essential in the recruitment of monocytes/macrophage, while Chemokine (C‐X‐C motif) ligand 3 (CXCL3) is essential for neutrophil recruitment (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}). These are induced to greater levels in the ischemic brain (Hori et al., [2012](#jnr24333-bib-0034){ref-type="ref"}; Wolinski & Glabinski, [2013](#jnr24333-bib-0080){ref-type="ref"}; Zaremba, Ilkowski, & Losy, [2006](#jnr24333-bib-0082){ref-type="ref"}). Minami et al. reported that the chemokine MCP‐1/CCL2 binding to its respective receptor CCR2 expressed on the brain endothelial surface, leads to dynamic reorganization of the actin cytoskeleton and structural alteration of tight junctions (TJs). This causes a gradual morphological change which was characterized with an upregulated vascular permeability (Stamatovic, Keep, Kunkel, & Andjelkovic, [2003](#jnr24333-bib-0071){ref-type="ref"}). The upregulated or increased vascular permeability leads to the formation of brain edema and is found to be a major reason for death with severe infarction (Ayata & Ropper, [2002](#jnr24333-bib-0005){ref-type="ref"}; Minami, Katayama, & Satoh, [2006](#jnr24333-bib-0060){ref-type="ref"}) (Figure [3](#jnr24333-fig-0003){ref-type="fig"}).

![Mechanism of action of IFN‐β. **(**a) Ischemic injury followed by reperfusion. Within hours of ischemia, upregulation of adhesion molecules expression (e.g., ICAM‐1, VCAM‐1, and E‐selectin,) on the brain endothelial surface. These upregulated adhesion molecules increase the influx of inflammatory cells (e.g., monocytes, neutrophils, B cells, and T cells) to the ischemic brain, causing Infarct formation. IFN‐β reduces the upregulated adhesion molecule expression (e.g., ICAM‐1, VCAM‐1, and E‐selectin) and helps in reducing the infarct formation by decreasing inflammatory cell influx into the brain. (b) After ischemic injury, resting microglial cells are activated and increase the release of matrix metalloproteinase 9 (MMP‐9), tumor necrosis factor α (TNF‐α), monocyte chemoattractant protein‐1 (MCP‐1), interleukin 1B (IL‐1B), IL‐8 which facilitate inflammatory cellinfiltration (monocytes, neutrophils, B cells, and T cells) at the injury site in the brain. Increased infiltration of inflammatory cells compromises the blood--brain barrier (BBB) integrity and leads to secondary brain injury, responsible for increased infarct area in the brain. IFN‐β impairs the ischemia‐induced chemokine (C‐C motif) ligand 3 (CCL3), Chemokine (C‐X‐C motif) ligand 3 (CXCL3), and MMP‐9 expressions and helps to reduce brain infarct. (c) Ischemic injury is followed with reperfusion. Reperfusion increases the peripheral immune cell infiltration (CD45hiCD11b+, CD11b+Ly6G+, CD4+, γδ T Cells) at brain injury and leads to BBB compromise; it leads to BBB disruption and secondary brain injury, results in infarct formation in the brain. IFN‐β lowers the number of infiltrating cells that is, CD45hiCD11b+, CD11b+Ly6G+, CD4+, γδ T Cells in ipsilateral side of the brain and shows a protective role in ischemic stroke by decreasing BBB disruption \[Colour figure can be viewed at <http://wileyonlinelibrary.com>\]](JNR-97-116-g003){#jnr24333-fig-0003}

Matrix metallopeptidase‐9 (MMP‐9), released throughout the course of ischemic injury, increases BBB permeability via degradation of extracellular matrix (ECM), TJs in brain endothelium facilitate the inflammatory immune cell infiltration into the CNS (Chaturvedi & Kaczmarek, [2014](#jnr24333-bib-0012){ref-type="ref"}; Lakhan et al., [2009](#jnr24333-bib-0052){ref-type="ref"}). Scientists have reported the significant effect of IFN‐β on the production of MMP‐9 and chemokines in MG, a major producer of inflammatory cytokines implicated as a mediator of neuroinflammation (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}). It was found that in the ischemic brain, there is a dramatic increase in the expression of CCL3, CXCL3, and MMP‐9 in the ipsilateral part but not in the contralateral part of the brain. IFN‐β treatment helps in reducing the expression of CCL3, CXCL3, and MMP. Kuo et al., have carried out a study to find IFN‐β's inhibitory effect lipopolysaccharide (LPS)‐induced primary MGs. Their results showed that IFN‐β decreased the expression of CCL3, CXCL3, and MMP‐9 in LPS‐activated MGs in a significant manner (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}) (Figure [3](#jnr24333-fig-0003){ref-type="fig"}).

Cerebral ischemic injury followed by reperfusion is mainly responsible for infiltration of peripheral immune cells consisting of T cells, neutrophils, and monocytes/macrophages, resulting in secondary brain injury eventually responsible for increasing the degree of brain infarction (Benakis et al., [2015](#jnr24333-bib-0008){ref-type="ref"}; Wang, Tang, & Yenari, [2007](#jnr24333-bib-0078){ref-type="ref"}). Scientists have also reported that throughout the course of ischemic injury, there is a significant rise in various cell counts including CD11b+Ly6G+ neutrophils and CD45hiCD11b+ monocytes/macrophages in the ipsilateral part of the ischemic brain. In addition, they found that IFN‐β treatment significantly helps in lowering the levels of these cells (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}) (Figure [3](#jnr24333-fig-0003){ref-type="fig"}).

As per previous reports, both CD4+T cells and γδ T cells also playa pathogenic role in ischemic stroke (Gelderblom, Arunachalam, & Magnus, [(2014)](#jnr24333-bib-0027){ref-type="ref"}; Shichita et al., [2009](#jnr24333-bib-0070){ref-type="ref"}). There is arise in the numbers of CD4+T cells and γδT cells in the ischemic brain and this leads to the BBB breakdown and increased infarct size associated with induction of MMP3 and MMP9. IFN‐β treatment reduces both CD4+T cell and γδT cell numbers and decreases the infarct size. IFN‐β treatment suppresses the infiltration of various peripheral immune cells like neutrophils, macrophages/monocytes, and CD4+T cells and γδT cells, providing a protective role in ischemic stroke (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}) (Figure [3](#jnr24333-fig-0003){ref-type="fig"}).

During ischemia, inflammatory processes lead to migration of peripheral blood leukocytes into brain parenchyma, regulated by the adhesion molecules. Adhesion molecules including E‐selectin, P‐selectin, ICAM‐1, and VCAM‐1 are expressed on the activated brain endothelial cell surface and are upregulated after ischemia. They are responsible for facilitating the influx of inflammatory cells and conferring BBB breakdown. Reports suggest that within hours of reperfusion in the middle cerebral artery occlusion/reperfusion (MCAO/R) model in rats, adhesion molecules were found to be upregulated in brain endothelial cells (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}; Lindsberg, Carpe, Paetau, Karjalainen‐Lindsberg, & Kaste, [1996](#jnr24333-bib-0054){ref-type="ref"}; Zhang, Chopp, Zhang, Jiang, & Powers, [1998](#jnr24333-bib-0083){ref-type="ref"}). Kuo et al. studied that 24‐hr post‐ischemia, there is a significant rise in ICAM‐1 and E‐selectin in the ischemic part of the brain. Further treatment with IFN‐β helps in reducing upregulated ICAM‐1 and E‐selectin in the ipsilateral hemispheres of animals induced with ischemic stroke. Also, there is an increase in VCAM‐1 expression in ischemic stroke, but IFN‐β treatment has not shown any effect on its expression (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}). They also studied IFN‐β effect on endothelial cell lines bEnd.3. Activation of bEnd.3 cell lines with TNF‐α upregulates ICAM‐1 and E‐selectin at both levels that is, at the genetic level and protein level. They found that IFN‐β treatment helps to obviate TNF‐α‐induced P‐selectin, ICAM‐1, and E‐selectin upregulation but failed inattenuating VCAM‐1 expression which is induced due to TNF‐α on the surface of the cell (Kuo et al., [2016](#jnr24333-bib-0051){ref-type="ref"}; Suárez, Wang, Manes, & Pober, [2010](#jnr24333-bib-0073){ref-type="ref"}) (Figure [3](#jnr24333-fig-0003){ref-type="fig"}). However, the beneficial effect of IFN‐β to counteract ischemic stroke injury remains controversial. It was reported by Maier et al. that IFN‐β failed to protect ischemic injury in a model of transient focal stroke (Maier, Yu, Nishi, Lathrop, & Chan, [2006](#jnr24333-bib-0055){ref-type="ref"}).

### 3.2.1. Limitations of IFN‐β therapy in ischemic stroke {#jnr24333-sec-0010}

Since the discovery of IFNs, IFN has progressed from a poorly understood antiviral substance to being FDA‐approved for the treatment of five disorders (Baron et al., [1991](#jnr24333-bib-0007){ref-type="ref"})**.** We have discussed the various mechanisms of IFN**‐**β and its therapeutic potential. However, certain side effects limit the use of IFN‐β (Pestka, [2007](#jnr24333-bib-0064){ref-type="ref"}). Although IFN‐β is usually safe and well tolerated, it causes certain adverse effects. IFNs not only cause local adverse events but systemic adverse reactions as well (Kolb‐Mäurer, Goebeler, & Mäurer, [2015](#jnr24333-bib-0045){ref-type="ref"}). After treatment with IFN‐β, patients have exhibited fatigue, myalgia, headache, malaise, and joint pain (Pestka, [2007](#jnr24333-bib-0064){ref-type="ref"}). Depression has been reported in patients with no prior psychiatric history following IFN‐β therapy (Fragoso et al., [2010](#jnr24333-bib-0022){ref-type="ref"}). Reduced doses of IFN‐β have elicited severe depression and altered tolerability, resulting in discontinuation of treatment (Asnis & De La Garza II, [2005](#jnr24333-bib-0003){ref-type="ref"}). Few studies have demonstrated that endogenous molecules like melatonin, a potent antioxidant and a regulator of circadian rhythm, maybe helpful in mitigating the depressive symptoms associated with IFN‐β (Hansen, Danielsen, Hageman, Rosenberg, & Gögenur, [2014](#jnr24333-bib-0033){ref-type="ref"}). Also, it has been reported that therapy of IFN‐β in combination with L‐methyl folate or S‐adenosyl methionine has varying degrees of outcomes in monotherapy or augmentation therapy for depression (Franscina Pinto & Andrade, [2016](#jnr24333-bib-0023){ref-type="ref"}). However, till date, no studies have been examined in therapeutic treatment of the IFN‐β‐related depressive disorder and should, therefore, be appraised as a possibility in future studies. Thus, IFN‐β therapy may serve as a substantial therapy for the treatment of acute ischemic stroke if the side effects of IFN‐β can be reduced and prevented.

4. CONCLUSION {#jnr24333-sec-0011}
=============

Inflammation and immunity are an essential and fundamental parts of the pathogenesis initiated by ischemic and reperfusion injury. Inflammatory cascade is responsible for initiation of early molecular events caused due to blood vessel occlusion and culminates in brain invasion by various inflammatory cells. CNS inflammation, cytotoxicity, BBB disruption, and peripheral immune cell infiltration at the injury site play important roles in secondary brain injury and lead to increased brain infarct. IFN‐β may play protective and multiphasic roles after ischemic stroke. This review focused on the neuroprotective role of IFN‐β in ischemic stroke. As there is a growing body of evidence indicating that inflammatory mediators are predominantly deleterious in the primary phase after ischemic stroke, IFN‐β may be a promising treatment option against ischemic stroke and may be salutary for future adjuvant therapy. With these preclinical findings, IFN‐β has entered the clinical level as a therapeutic agent for ischemic stroke. However, some more substantial findings are required to be carried out in the future for better understanding of ischemic stroke in relation with CNS inflammation, cytotoxicity, BBB dysfunction, and the therapeutic potential of IFN‐β in ischemic stroke.
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